Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

This study is testing whether adding a second immunotherapy drug (fianlimab) to an existing immunotherapy drug (cemiplimab) after targeted radiation therapy improves outcomes for patients with advanced clear cell kidney cancer (clear cell renal cell carcinoma) that has spread to other areas. The radiation is intended to stimulate the immune system before immunotherapy. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with clear cell kidney cancer confirmed by biopsy - You have between 1 and 5 metastatic tumors that are measurable on scans - All of your tumor sites (including the primary tumor, if present) are able to receive stereotactic body radiation therapy (SBRT) - You have not yet received systemic cancer treatment for this diagnosis **You may NOT be eligible if...** - You have already received systemic treatment for kidney cancer - You have more than 3 treated brain metastases, or brain metastases larger than 2 cm - You have active autoimmune disease requiring systemic treatment - You are unable to receive radiation therapy or immunotherapy for medical reasons Talk to your doctor to see if this trial is right for you.